CAR T-Cells in Multiple Myeloma Are Ready for Prime Time

The survival of patients with multiple myeloma (MM) has been dramatically improved in the last decade thanks to the incorporation of second-generation proteasome inhibitors (PI), immunomodulatory drugs (IMID), and, more recently, anti-CD38 monoclonal antibodies (MoAb). Nevertheless, still, a major p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Otero, Paula, Prósper, Felipe, Alfonso, Ana, Paiva, Bruno, Miguel, Jesús F. San
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694626/
https://www.ncbi.nlm.nih.gov/pubmed/33172026
http://dx.doi.org/10.3390/jcm9113577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694626/
https://www.ncbi.nlm.nih.gov/pubmed/33172026
http://dx.doi.org/10.3390/jcm9113577

Ejemplares similares